Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Current Deferred Revenue: 2019-2024

Historic Current Deferred Revenue for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $257,000.

  • 4D Molecular Therapeutics' Current Deferred Revenue fell 72.62% to $360,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $360,000, marking a year-over-year decrease of 72.62%. This contributed to the annual value of $257,000 for FY2024, which is 5.86% down from last year.
  • According to the latest figures from FY2024, 4D Molecular Therapeutics' Current Deferred Revenue is $257,000, which was down 5.86% from $273,000 recorded in FY2023.
  • In the past 5 years, 4D Molecular Therapeutics' Current Deferred Revenue ranged from a high of $19.8 million in FY2020 and a low of $257,000 during FY2024.
  • Its 3-year average for Current Deferred Revenue is $830,000, with a median of $273,000 in 2023.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Current Deferred Revenue increased by 1.77% in 2020, and later plummeted by 86.07% in 2023.
  • Over the past 5 years, 4D Molecular Therapeutics' Current Deferred Revenue (Yearly) stood at $19.8 million in 2020, then tumbled by 74.31% to $5.1 million in 2021, then crashed by 61.49% to $2.0 million in 2022, then tumbled by 86.07% to $273,000 in 2023, then declined by 5.86% to $257,000 in 2024.